The specific delivery of ribonucleic acid (RNA) interfering molecules to disease-related cells is still a critical blockade for in vivo systemic treatment. Here, this study suggests a robust delivery carrier for targeted delivery of RNA-interfering molecules using galactosylated magnetic nanovectors (gMNVs). gMNVs are an organic-inorganic polymeric nanomaterial composed of polycationics and magnetic nanocrystal for delivery of RNA-interfering molecules and tracking via magnetic resonance (MR) imaging. In particular, the surface of gMNVs was modified by galactosylgluconic groups for targeted delivering to asialoglycoprotein receptor (ASGPR) of hepatocytes. Moreover, the small interfering RNAs were used to regulate target proteins related with low-density lipoprotein level and in vivo MR imaging was conducted for tracking of nanovectors. The obtained results show that the prepared gMNVs demonstrate potential as a systemic theragnostic nanoplatform for RNA interference and MR imaging. 
Introduction
In ribonucleic acid (RNA) interference (RNAi), small interfering RNA (siRNA) can inhibit gene expression by destroying specific messenger RNA molecules [1, 2] . Since its discovery, the ability of RNAi to directly affect protein expression has led to its prominent use in existing or new therapeutic methods against rare diseases [3] . In general, liposomes [4, 5] , charged polymers [6, 7] , and viral vectors [8, 9] have been widely used to deliver RNAi molecules. However, the exact delivery method of RNAi molecules has not been established, as their small size (∼20 nucleotides) makes controlling RNA molecules difficult [10, 11] . Recently, although multi-structure siRNAs have been created in an attempt to solve the delivery problem for such small RNA molecules [12, 13] , however, these reagents lack targeting moieties and are at risk of inducing immune responses. Thus, biomarker-specific RNAi strategy and tracking systems via non-invasive imaging tools are essential for effective RNAi against target cells [14] . We thus propose galactosylated magnetic nanovectors (gMNVs) to deliver siRNAs toward target cells and for magnetic resonance (MR) imaging. gMNVs consist of highly crystalline magnetic nanoparticles (manganese ferrite nanoparticles, MFNPs), positively charged polymers (branched polyethylenimine, bPEI) and disaccharides (galactosylgluconic acid, figure 1 ). In particular, gMNVs target the asialoglycoprotein receptor (ASGPR), which binds to galactosylgluconic acid. ASGPR is a C-type lectin-a carbohydrate-binding protein-that is abundantly expressed on the surface of hepatic cells (∼5 × 10 5 ASGPR molecules/cell) [15, 16] , making it a good delivery target for liver sites. To evaluate the effectiveness of gMNVs in siRNA transfection, the protein convertase subtilisin/kexin 9 (PCSK9) was selected as the gene-silencing target. PCSK9 acts as a chaperone that promotes the degradation of the low-density lipoprotein receptor (LDLR). Down-regulation of PCSK9 increases LDLR expression and promotes LDL uptake into hepatocytes. An elevated LDL concentration in the blood is one of the main causes of hypercholesterolemia [17, 18] . Thus, PCSK9 gene silencing by siRNA can be an effective therapeutic strategy of hypercholesterolemia. In this study, the physicochemical properties of gMNVs were confirmed by Fourier transform infrared (FT-IR) spectroscopy, dynamic laser scattering analysis, and transverse relaxation time (T2)-weighted MR imaging. The loading capacity of gMNVs for siRNA and MR imaging contrast agents were evaluated by in vitro dark-field and fluorescence microscopy. The in vivo MR imaging and histological analysis after the intravenous injection of gMNVs were also performed to confirm the siRNA-delivery and targeting ability of gMNVs to hepatocyte. Finally, the regulated LDLR-expression level of ASGPR-expressing cells after the transfection of gMNVs /siRNA was investigated by immunoblotting analysis.
Materials and methods

Materials
Iron (III) acetylacetonate, manganese (II) acetylacetonate 1,2-hexadecanediol, dodecanoic acid, dodecylamine, benzyl ether, bPEI (25 000 Da), 3-aminopropyltrimethoxysilane (APTMS), ammonium hydroxide solution (30%), glutaraldehyde solution (25%), and lactobionic acid (galactosylgluconic acid) were purchased from Sigma Aldrich Chemical Co. (USA). Dicyclohexylcarbodiimide (DCC) and N-hydroxysulfosuccinimide (NHS) were purchased from Pierce (USA). Phosphate-buffered saline (PBS; 10 mM, pH 7.4), Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum, and antibiotic-antimycotic solution were purchased from Life Technologies (USA, Gibco brand). HepG2 and MCF7 cell lines were purchased from American Tissue Type Culture (USA). Diethylpyrocarbonate (DEPC)-treated water was purchased from Biosesang Inc. (Korea).
PCSK9 siRNA (siPCSK9) and the scrambled siRNA (siScr) were purchased from Integrated DNA Technologies, Inc. (USA). The siPCSK9 sense strand was 5'-AAGAUAAAU-GUCUGCUUGCUUGGGUGG-3', and the antisense strand was 5'-ACCCAAGCAAGCAGACAUUUAUCTT-3'. The fluorescein isothiocyanate (FITC)-tagged siRNA (siRNA-FITC) was purchased from Bioneer Inc. (SN-1003, SN-1022, USA). Ultrapure deionized water was used for all syntheses. All other chemicals and reagents were of analytical grade.
Synthesis of MFNPs
MFNPs were synthesized using a previously described thermal decomposition method [19, 20] . Briefly, 2 mmol iron (III) acetylacetonate, 1 mmol manganese (II) acetylacetonate, 10 mmol 1,2-hexadecanediol, 6 mmol dodecanoic acid, 6 mmol dodecylamine, and 20 mL benzyl ether were mixed in a threenecked flask and stirred. The mixture was preheated to 100°C under nitrogen for 30 min to remove residual O 2 and H 2 O. The preheated mixture was then heated to 200°C (10°C min −1 ) for 2 h with a water-cooled condenser and refluxed at 300°C for 30 min under nitrogen. The reactants were removed from the heat source and allowed to cool to room temperature before purifying with excess ethanol. A black precipitate was obtained by centrifugation (1811 g for 10 min) and dissolved in 2 mL hexane in the presence of 0.16 mmol dodecanoic acid. The mixture was centrifuged again (1811 g for 10 min) to remove any undispersed residue. The dark brown supernatant was purified by adding excess ethanol, mixed by ultrasonication, and centrifuged (1811 g for 10 min) to remove the solvent. The precipitate was resuspended in 5 mL hexane.
Preparation of gMNVs
The gMNVs were fabricated in the following order: MFNPs, APTMS, glutaraldehyde, bPEI, and galactosylgluconic acid ( figure 2(a) ). First, for synthesis of APTMS-coated MFNPs (MA), 20 mg MFNPs were added to 30 mL ethanol, followed by the addition of 2 mL deionized water. To this solution, 1.5 mL ammonium hydroxide solution and 1.0 mmol APTMS were added. The mixture was sonicated for about 8 h, and the resulting product was separated using a permanent magnet, thoroughly washed with deionized water, and dissolved in 20 mL PBS solution containing 2.0 mmol glutaraldehyde to get the glutaraldehyde-coated MA (MAG). The mixture was incubated at room temperature for 1 h with vigorous stirring. This reactant was again separated using a permanent magnet, thoroughly washed with excess PBS, and resuspended in 20 mL PBS. Then, 5.6 μmol bPEI was dissolved in 20 mL PBS and mixed with the reactant solution. The mixture was then incubated at room temperature for 1 h with vigorous stirring (bPEI-immobilized MAG, MAG-bPEI). The resulting reactant was washed with PBS several times and resuspended in dimethyl sulfoxide (DMSO). Galactosylgluconic acid was then conjugated with the resulting reactant using DCC-NHS crosslinkers. For this conjugation process, 0.23 mmol galactosylgluconic acid, 0.34 mmol DCC, and 0.34 mmol NHS were dissolved in DMSO. The mixture was added to the MAG-bPEI solution, and incubated for 4 h with vigorous stirring. Finally, gMNVs were obtained by washing the above mixture thoroughly with DMSO and dispersed in DEPC-treated water.
The chemical structure of gMNVs was confirmed by FT-IR (spectrum two, PerkinElmer, USA). The morphology of gMNVs was observed by transmittance electron microscopy (JEOL-1011, JEOL Ltd., Japan) and the diameter and zeta potential of gMNVs were analyzed by a dynamic laser scattering analyzer (ELS-Z, Otsuka Electronics, Japan). To determine gMNVs potential as a MR imaging contrast agent, experiments were performed using a 1.5 T clinical MR imaging instrument with a micro-47 surface coil (Intera, Philips Medical system, Netherlands) against various concentrations of gMNVs. The T2 relaxivities (R2) of gMNVs were measured at room temperature with a T2 mapping sequence in which following parameters were used: point resolution = 156 μm × 156 μm; section thickness = 0.6 mm; TE = 20, 40, 60, 80, 100, 120, 140, and 160 ms; TR = 4000 ms; and acquisition number = 2. R2 was defined as 1/T2 with the unit s −1 . The reflexivity coefficient, r2 (s −1 mM −1 ), equaled the ratio of R2 to the gMNV concentration. The susceptibility toward a magnetic field was evaluated using a vibrating sample magnetometer (MODEL-7407, Lake Shore Cryogenics Inc., USA).
Evaluation of siRNA-loading capacity of gMNVs
To evaluate the siRNA-loading capacity for gMNVs, 10 μL of gMNVs was prepared at concentrations ranging from 0.6 to 4.8 μg/μL and added to the 5 μL of siRNA solution containing 0.15 μg siRNA (w/w ratio: 60 to 320, figure 4). The mixture was gently vortexed and incubated at room temperature for 20 min Gel electrophoresis was performed after loading the gMNVs/siRNA complex in each lane (eight lanes, 2% agarose gel, 30 min, 100 V) to determine the ratio of gMNVs/ siRNA complex needed to act as an siRNA-transfection agent. The siRNA-loading capacity of gMNVs determined in this step was used in the following experiments.
In vitro cytotoxicity of gMNVs
The cytotoxicity of gMNVs in HepG2 cells was evaluated using an MTT cell proliferation assay kit (Roche, Switzerland). HepG2 cells were seeded in a 96-well plate at a density of 2.0 × 10 4 cells/well and incubated at 37°C in a humidified atmosphere with 5% CO 2 . After a 24 h incubation, HepG2 cells were treated with gMNVs and gMNVs/siRNA at various concentrations for 24 h. The highest concentration, 720 μg mL −1 , was sequentially diluted two-fold, resulting in eight different dilutions. Each well was treated with 200 μL gMNVs. The cells were then washed with 100 μL PBS, and 100 μL fresh RPMI 1640 was added. The cells were treated with the MTT assay solution according to the manufacturer's instructions. Cell viability was evaluated spectrophotometrically using a microplate reader (Synergy H4 hybrid reader, BioTek instruments Inc., USA) at 575 nm (reference wavelength at 650 nm). All cytotoxicity analyses were performed in triplicate. Cell viability was determined by the ratio of the absorbance values for the gMNV-treated cells to those for the control cells. Cytotoxicity analyses for gMNVs and other synthesized bPEI-based transfection agents were also performed; the results were determined by calculating the IC 50 values.
Evaluation of gMNVs targeting ability
To evaluate the targeting ability of gMNVs, dark-field microscopy, fluorescence microscopy, and in vitro MR imaging were performed. Experiments were conducted using HepG2 cells, with ASGPR-deficient MCF7 cells as a control.
For dark-field microscopic analysis, HepG2 and MCF7 cells (2.0 × 10 4 cells/well) were seeded in 4-well plates containing coverslips and incubated at 37°C for 24 h. gMNVs were added and incubated for 1 h at 37°C before the cells were washed with PBS and fixed with 4% paraformaldehyde. The binding affinity of gMNVs to cells was assessed using light-scattering images obtained by inverted microscopy (BX51, Olympus, Japan) with a high numerical aperture darkfield condenser (U-DCW, Olympus, Japan). The same experiment was performed using gMNVs/siRNA complex to investigate ASGPR-mediated endocytosis of gMNVs/siRNA.
The ASGPR-binding and siRNA-delivery abilities of gMNVs were observed by fluorescence microscopy (BX51, Olympus, Japan); siRNA-FITC used to examine the endocytosis of gMNVs. First, HepG2 and MCF7 cells were seeded overnight at a density of 2.0 × 10 4 cells/well in 4-well plates containing coverslips. One coverslip was washed with cold PBS three times; the cells were then fixed in a 4% paraformaldehyde solution for 10 min at room temperature. The coverslip was washed with cold PBS, and 500 μL serum-free media containing gMNVs/siRNA-FITC were added. For the other coverslip, the culture medium was removed, and the cells were treated with 500 μL serum-free media containing gMNVs/siRNA-FITC. The cells were incubated with gMNVs/siRNA-FITC for 1 h at 37°C in a CO 2 atmosphere. After incubation, all coverslips were washed three times with cold PBS, and unfixed slides were fixed in paraformaldehyde solution. The fixed slides were imaged by fluorescence microscopy.
To evaluate the capacity of gMNVs to target ASGPR, an in vitro R2 analysis was performed in PBS, gMNV-untreated cells, and gMNV/siRNA-treated cells using T2 mapping MR imaging sequence. The gMNV/siRNA-treated cells were prepared by incubating HepG2 and MCF7 cells (1.0 × 10 7 cells/tube) with 3 mL gMNVs/siRNA (0.1 mg mL −1 of gMNVs) for 4 h at 37°C. Any unbound gMNVs were rinsed away, and in vitro cell MR imaging was performed. T2-weighted MR imaging was performed using the following parameters: point resolution = 156 μm × 156 μm, section thickness = 0.6 mm, TE = 60 ms, TR = 4000 ms, and acquisition number = 1.
In vitro regulation of LDLR expression
To investigate the expression level of LDLR after transfecting siPCSK9 with gMNVs, the harvested HepG2 cells were washed twice with PBS and lysed directly in the 12 well plates using 100 μL NUN buffer [21] containing 0.33 M NaCl, 1.1 M urea, 1% Nonidet P-40, 25 mM HEPES (pH 7.6), and proteinase inhibitors (1 mM dithiolthreitol, 10 μg mL −1 leupeptin, 5 μg mL −1 pepstatin A, 1 mM phenylmethylsulfonyl fluoride, 2 μg mL −1 aprotinin, and 50 μg mL −1 N-acetyl-leucine-leucine-norleucinal). The cell lysates were harvested and vortexed at room temperature for 10 min to fully release the proteins. The lysates were cleared by centrifugation at 20 000 g for 15 min at 4°C, and the supernatants were collected as whole-cell lysates. After quantitation of proteins, aliquots of proteins were subjected to 8% SDS-PAGE and transferred onto nitrocellulose enhanced chemiluminescence membranes (GE Healthcare), and immunoblotting analyses were performed using the SuperSignal West Pico Chemiluminescent Substrate System (Pierce).
In vivo MR imaging and histological analysis
The ability of gMNVs to target ASGPR was assessed in vivo using T2-and T2*-weighted MR imaging and histological analysis. gMNVs/siRNA-FITC complex was prepared, and MR imaging was performed in wild-type C57BL/6 mice before injection and after 1 h post-intravenous injection of gMNVs/siRNA-FITC using a 3.0 T clinical MR imaging instrument (Achieva, Philips Medical System, Netherlands) with the following conditions: T2-weighted turbo spin echo sequence, TR = 1054 ms, TE = 70 ms, number of average = 2, point resolution = 98 μm × 98 μm, slice thickness = 2 mm, T2*-weighted fast field echo sequence, TR = 450 ms, TE = 5.8 ms, number of average = 1, point resolution = 195 μm × 195 μm, and slice thickness = 2 mm. The histogram analysis for region of interest (ROI) on T2-weighted MR images was conducted using Image J software. After MR imaging, the mouse livers were harvested and stained with hematoxylin and eosin (H&E) in a darkroom to avoid quenching the FITC. The stained slides were observed with bright-field and fluorescence microscopy to analyze the histological morphology of the livers and detect any gMNVs/ siRNA-FITC. 
Biodistribution
To investigate the biodistribution of gMNVs/siRNA complex after the intravenous injection, the ex vivo MR imaging for the lysate of extracted tissues was performed. Specifically, gMNVs/siRNA complex was prepared by 200 μg of gMNVs and 0.83 μg of siScr (w/w ratio: 240) for 20 min at room temperature and injected into the tail vein of C57BL/6 mice (n = 3). After 24 h, the mice were euthanized and specific organs (brain, liver, spleen, and kidney) were extracted. The extracted organs were immersed using RIPA buffer (Biosesang Inc., Republic of Korea) and subsequently homogenized by tissue homogenizer (PRO 200, PRO Scientific Inc., USA). The bare gMNVs and PBS were respectively injected into the tail vein of C57BL/6 mice (n = 3 per each group) as control groups. The R2 values were obtained by analysis of the T2 mapping MR imaging data. The biodistribution data was represented by relative R2 value for each organ based on the R2 value of the PBS-injection group.
Statistical analysis
All data are presented as mean ± standard deviations of nindependent measurements and Student's t-test was used for statistical analysis. The null hypothesis was rejected at the 95 ∼ 99% confidence level and P-values less than 0.01 were considered significant.
Results and discussion
In this study, the use of gMNVs for targeted RNAi in liver cells, while allowing simultaneous MR imaging, was developed. MFNPs were chosen as the basis for the fabricating gMNVs. Magnetic nanoparticles are effective MR imaging probes for noninvasive in vivo monitoring of molecular and cellular events [22] . In particular, we chose MFNPs for their magnetic properties because our previous study found that MFNPs exhibit 160% stronger MR contrast than do iron oxide nanoparticles [23] .
The chemical structure of gMNVs and the product of each synthesis step (MA, MAG, MAG-bPEI) were assessed with FT-IR ( figure 2(b) ). The Fe-O peak from MFNPs (580 cm −1 , data not shown) was observed at the synthesized gMNVs and the carboxyl peaks (C=O stretch, 1550 cm −1 , 1660 cm −1 ) for dodecanoic acid disappeared after the synthesis of MA because the dodecanoic acid was eliminated by EtOH washing. In the characteristic band of MAG-bPEI, N-H peaks (3287 cm −1 : stretch, 1589 cm −1 : deformation) were observed due to the presence of bPEI. In the characteristic band of gMNVs, the carboxyl group disappeared, whereas the N-H amide peak (3100 cm −1 : stretch, 1648 cm −1 : deformation) reappeared after DCC-NHS crosslinking; the stretch of hydrogen bonds of galactosylgluconic acid (broad peak on 3400 ∼ 3200 cm −1 ) remained. The N-H amine peak (from bPEI, 1589 cm −1 : deformation, 3287 cm
: stretching) was also visible in gMNVs. These results mean that the amine groups from bPEI remained for gMNVs. The amine group in gMNVs promotes siRNA loading via ionic charge interactions, and galactosylgluconic acid facilitates the targeting of ASGPR. These results confirm that gMNVs were fabricated near to the first design for targeted RNAi and simultaneous MR imaging of the liver cells.
To evaluate the targeting ability of gMNVs, dark-field microscopy, fluorescence microscopy and in vitro MR imaging were performed. The hydrodynamic diameter of gMNVs measured in aqueous medium by dynamic later scattering was 404.5 ± 84.2 nm ( figure 3(b) ). The zeta potential of gMNVs was 14.0 ± 0.4 mV. gMNVs were designed to bind siRNAs via the natural interactions of the charges [24, 25] between the negatively charged siRNAs and the positively charged bPEI. Therefore, the measured zeta potential of gMNV demonstrated that gMNV might contain a loading capacity for siRNA.
To evaluate the ability of gMNVs to serve as MR imaging contrast agents, r2 ( figure 3(c) ) and magnetic susceptibility analyses ( figure 3(d) ) were performed. R2 relaxivity coefficient was calculated against Fe concentrations, and an r2 value of 176.25 s −1 mM −1 was obtained. Magnetite nanoparticles have previously yielded r2 values ranging from 20 to 110 s −1 mM −1 based on cluster size [26] . A high r2 value for gMNVs is believed to be caused by the presence of Mn components in MFNPs. gMNVs also exhibited superparamagnetic behavior in the magnetic susceptibility analysis. These results demonstrate that gMNVs have sufficient potential as an MR imaging contrast agent.
As a result of gel electrophoresis assay, the siRNA loading capacity for gMNVs was evaluated with 240 w w −1 ratio ( figure 4, lane VII) . The bright bands from siRNA were not observed at 2 and 4 w w −1 ratios for bPEI/siRNA complexes. In addition, siRNA molecules were not released from gMNVs/siRNA complexes over 240 w w −1 ratio. A bright band indicates siRNA presence, with its intensity directly proportional to the amount of siRNA. The absence of a bright band means that the siRNA is completely bound by gMNVs. Furthermore, cytotoxicity of gMNVs and gMNVs/siRNA in HepG2 cells was assessed using MTT assay at eight different concentrations ( figure 5(a) ). Neither bare gMNVs nor gMNVs/siRNA complex significantly damaged the HepG2 cells at the concentrations used in this study; 80% cell viability was exhibited even at four times the concentration of gMNVs used for the experiments.
The IC 50 values were measured for gMNVs, bPEI, galactosylgluconic acid-conjugated bPEI (gPEI), and MAGbPEI products that were formed before conjugation of galactosylgluconic acid ( figure 5(b) ). The IC 50 value of gMNVs was 2.0 mg mL −1 , approximately 100 ∼ 400% higher than the other materials. In particular, the IC 50 values of the galactosylgluconic acid-conjugated materials, gMNVs and gPEI, were higher than those of the MAG-bPEI and bPEI, suggesting that the galactosylgluconic acid conjugation reduced the net positive charge caused by the bPEI group. The cellular lipid membranes were negatively charged [27] , and thus gMNVs yielded little cytotoxicity because of chargeneutralization by the presence of galactosylgluconic acid. Positively charged particles, conversely, bound to cellular membranes nonspecifically, causing cytotoxicity [28] . These results suggest that galactosylgluconic acid is bound to the gMNV surface.
The R2 values were calculated by inversing T2 intensity measuring from the T2 mapping image, yielding 0.65 and 0.71 s −1 for the HepG2 and MCF7 cells lacking gMNVs, respectively. Cells were then treated with gMNVs for 4 h and washed with PBS. The resulting R2 values were 1.04 and 0.67 s −1 for the HepG2 cells and MCF7 cells, respectively. In figure 5(c) , the R2 values were represented to relative R2 intensity value based on the R2 value of PBS. The increase in R2 indicates that T2 was shorter than before treatment with gMNVs, suggesting that gMNVs bound to HepG2 cells specifically due to an abundance of ASGPR. Moreover, the cellular affinity of gMNVs was investigated using dark-field microscopy ( figure 5(d) ), a simple, effective, and low-cost technique for confirming the interactions between nanoparticles and cells [29] . For gMNVs, nonspecific binding to both HepG2 and MCF7 cells was observed ( figure 5(d) , yellow dots), as gMNVs were positively charged in the presence of bPEI. After siRNA loading, the surface charge of gMNVs was neutralized, and gMNVs bound to the HepG2 cells specifically. The presence of siRNA in gMNVs was further evaluated by fluorescence microscopy ( figure 5(e) ). Fluorescence microscopic images were obtained after treatment of gMNVs/siRNA-FITC, and green fluorescence was observed in HepG2 cells treated with gMNV/siRNA-FITC. This result confirmed that gMNVs bound to HepG2 cells via siRNA, indicating that gMNVs served as a siRNA carrier.
In the result of MR imaging, an increase of the T2-signal intensity was observed in the liver (yellow dash lines in figure 6(a) ) after the intravenous injection of gMNVs into a tail vein. To get more obvious images of the gMNVs/siRNAtarget region, the T2*-weighted MR imaging was performed. T2*-weighted MR images displayed the magnetic susceptibility effect much more than T2-weighted MR images because gMNVs are the T2 contrast agent that generate the magnetic field inhomogeneity by inducing the local magnetic field and this enhanced the T2* relaxation decay of nearby protons [30] . For quantitative study of MR images, the histogram analysis was performed ( figure 6(b) ). The relative T2 intensity of ROI was calculated by dividing T2 intensity of ROI by muscular tissue. The peak of histogram at pre-injection is shifted left approximately 0.5, 1 h after injection of gMNVs/siRNA. The left-shift of the peak means that the T2 time of ROI was shorter than before the injection of gMNVs/ siRNA. This phenomenon is also observed in MR images by contrast enhancement effect. In histological analysis based on H&E staining, there are no critical damages in the tissue assay. Furthermore, bright green spots were observed by fluorescence microscopy and bright-field images were also obtained for comparison ( figure 6(c) ). The green spots mean the presence of gMNVs/sRNA-FITC and this result demonstrates that gMNVs specifically bind to liver cells because of the abundance of ASGPR in hepatocytes [15, 16] and would be ideal for the in vivo delivery of siRNA.
The R2 value is relatively correlated with the contents of magnetic components in the tissues. Therefore, biodistribution of gMNVs/siRNA could be analyzed by the measurement of R2 intensity for interrogated tissues by using MR imaging. Both the bare gMNVs and gMNVs/siRNA complex had the galactosylated group, so they could bind to ASGPR on the membrane of liver cells ( figure 7) . The liver tissue treated with gMNVs/siRNA exhibited approximately 120% higher relative R2 intensity compared to the bare gMNVstreated control (p 0.088). = In the case of the spleen, however, the relative R2 intensity for the bare gMNVs-injection group was approximately 140% higher compared to the gMNVs/siRNA-injection group; this is because the bare gMNVs exhibited strong positive charge and might be easily captured by reticuloendothelial system [31] [32] [33] . Furthermore, both the brain and kidney exhibited similar tendencies in relative R2 intensity for each groups. These results demonstrated that gMNVs/siRNA was delivered to the liver site without unwanted accumulation in the brain and kidney.
For verifying the ability of gMNVs as nanovectors, the expression levels of LDLR after the transfection of siRNA using gMNVs in HepG2 cells were evaluated via immunoblotting and represented by the relative expression levels of LDLR (figure 8, baseline: expression levels of LDLR in the siScr group). The amount of LDLR protein increased after siPCSK9 was transfected with gMNVs rather than with siScr. If siPCSK9 has delivered to ASGPR-expressing cells by gMNVs, it inhibited the transcription of messenger RNA regulated expressing of PCSK9, and then the intracellular expressing level of PCSK9 was decreased. PCSK9 acts as a chaperone that promotes the degradation of LDLR. Downregulation of PCSK9 causes the increase of LDLR expression and promotes LDL uptake into hepatocytes through LDLR. It has already been reported for this phenomenon that LDLR expression is regulated by PCSK9 [34, 35] , with the decrease of PCSK9 levels leading to a decrease in LDL levels in the blood. Because an elevated LDL concentration in the blood is one of the main causes of hypercholesterolemia, the siPCSK9 may be help to lessen symptoms of it and gMNVs is also expected to be useful to siRNA delivery.
Conclusions
In summary, we developed a gMNV that could specifically elicit RNAi while allowing simultaneous MR imaging. As previously reported by this group [19] , the usefulness of galactosylgluconic acid as a targeting moiety toward diseaserelated cells expressing ASGPR was proved once again. The surface modification of gMNVs using galactosylgluconic groups gives biocompatibility by neutralizing the positive charge of bPEI. The targeted imaging ability of gMNVs was evaluated by in vivo MR imaging and in vitro microscopic assay. The targeted delivery of siRNAs to ASGPR-expressing cells using gMNVs was confirmed and the regulation of protein expression by delivered siRNA was also verified. In Figure 7 . Biodistribution data of gMNVs/siRNA complex in C57BL/6 mice measured by MR imaging analysis (*p < 0.01, **p < 0.1). future work, gMNVs would be applied to RNAi therapeutics using various RNA-interfering molecules and also be verified for ability of in vivo gene regulation. We believe that gMNVs would be useful for in vivo siRNA delivery and as a robust therapeutic agent.
